Last reviewed · How we verify
Laron-type isolated somatotropin defect
Approved treatments
- Increlex · Children's Hospital Medical Center, Cincinnati
- MECASERMIN RINFABATE · Insmed
- Increlex · Ipsen Inc
Increlex works by mimicking the action of insulin-like growth factor 1 (IGF-1) to stimulate growth in individuals with Laron syndrome.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Laron-type isolated somatotropin defect patent landscape — cliff calendar, originator estates, attackable patents
- Laron-type isolated somatotropin defect treatment landscape brief
- Laron-type isolated somatotropin defect treatment updates RSS
Frequently asked questions about Laron-type isolated somatotropin defect
What drugs treat Laron-type isolated somatotropin defect?
Tracked treatments include Increlex, MECASERMIN RINFABATE.
What is the treatment for Laron-type isolated somatotropin defect?
Standard treatment for Laron-type isolated somatotropin defect includes Increlex, MECASERMIN RINFABATE. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Laron-type isolated somatotropin defect patent cliff · Laron-type isolated somatotropin defect CI report
- Treatment: Increlex · Children's Hospital Medical Center, Cincinnati
- Treatment: MECASERMIN RINFABATE · Insmed
- Treatment: Increlex · Ipsen Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing